The FDA has approved Casgevy, a gene therapy using CRISPR technology, for children aged 2 and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). This therapy modifies patients' own stem cells to increase fetal hemoglobin, reducing sickle cell crises and transfusion needs. Clinical trials showed significant efficacy and safety in younger children, expanding treatment options for these serious blood disorders. The approval was expedited under the FDA's priority programs, highlighting its potential impact on pediatric care.
Guggenheim Investments declared distributions for multiple closed-end funds, including Advent Convertible Income Fund and Guggenheim Strategic Opportunities Fund, with payments scheduled for July 31, 2026. These distributions may include income, capi...
AI/R Avenue Code, a subsidiary of AI/R, has achieved Google's Gemini Enterprise competency, recognizing its expertise in deploying advanced AI solutions securely in enterprises. This certification highlights their strengths in security, workflow auto...
Maple Finance, an onchain lending protocol, reached $5 billion in assets under management and over $2 billion in active loans, marking record highs. The protocol supports Robinhood's new Earn product by providing backend infrastructure using its syru...
A statue of Bitcoin's creator, Satoshi Nakamoto, was unveiled at the New York Stock Exchange on December 10, 2025, coinciding with Twenty One Capital's debut on the NYSE. The sculpture, part of a series symbolizing Bitcoin's capped supply of 21 milli...
Kayne Anderson Energy Infrastructure Fund disclosed its unaudited balance sheet as of June 30, 2026, showing net assets of $2.7 billion and a net asset value (NAV) per share of $16.02. The fund's asset coverage ratio was robust at 633% for senior sec...
